Contact   About this website

BELGIAN BIOSAFETY SERVER

[Home Page] [Previous Menu] [Search]

Table 2: Clinical data on the approved gene therapy clinical trials in Belgium
(Authors: M. Sneyers and M. Goossens - Last revised: July 28, 2010 )

n°	Indication category	Disease	Therapeutic approach	Transferred nucleic acid	Method of transfer	Administered biological material	Route of administration
B-GT/1	Cancer therapy	Newly diagnosed or recurrent Glioblastoma multiforme	Suicide gene/ pro drug	Thymidine Kinase (HSV-TK1), neomycin resistance (NeoR)	Amphotropic Murine Leukemia Virus	Retroviral vector producing cells (PA 317)	Intratumoral
B-GT/2	Cancer therapy	Newly diagnosed previously untreated Glioblastoma	Suicide gene/ pro drug	Thymidine Kinase (HSV-TK1), neomycin resistance (NeoR)	Amphotropic Murine Leukemia Virus	Retroviral vector producing cells (PA 317)	Intratumoral
B-GT/3	Cancer therapy	Squamous cell carcinoma of the Head and Neck	Tumor suppressor gene	Wild-type p53	Human Adenovirus serotype 5	Recombinant Adenovirus D (E3, E1A, E1B, pIX)	Intratumoral
B-GT/4	Cancer therapy	Non-Small Cell Lung Cancer	Tumor suppressor gene	Wild-type p53	Human Adenovirus serotype 5	Recombinant Adenovirus D (E3, E1A, E1B, pIX)	Intratumoral
B-GT/5	Cancer therapy	Malignant melanoma, Non-Small Cell Lung Cancer, Squamous cell carcinoma of the Head and Neck, Bladder transitional cell carcinoma	Immunotherapy	HLA-A1 restricted CTL epitope of MAGE-1 and MAGE-3 genes	Canarypox Virus (ALVAC)	Recombinant Canarypox Virus	Intradermal/ Subcutaneous
B-GT/6	Cancer therapy	Metastatic adenocarcinoma of the Breast	Immunotherapy	Muc-1 and Interleukine 2 (IL-2)	Attenuated Vaccinia Virus (Copenhagen Strain)	Recombinant Attenuated Vaccinia Virus	Intramuscular
B-GT/7	Cancer therapy	Recurrent squamous cell carcinoma of the Head and Neck	Tumor suppressor gene	Wild-type p53	Human Adenovirus serotype 5	Recombinant Adenovirus D (E3, E1A, E1B)	Intratumoral
B-GT/8	Cancer therapy	Ovarian and primary peritoneal cancer	Tumor suppressor gene	Wild-type p53	Human Adenovirus serotype 5	Recombinant Adenovirus D (E3, E1A, E1B, pIX)	Intraperitoneal
B-GT/9	Cancer therapy	Non-hematologic malignancies	Tumor colonization	Not relevant	Not relevant	Genetically modified Salmonella typhimurium bacillus	Intratumoral
B-GT/10	Infectious disease	AIDS	Immunotherapy	vCP-1452	Attenuated Canarypox Virus (ALVAC)	Recombinant Canarypox Virus	Intramuscular
B-GT/11	Cancer therapy	Metastatic Breast Cancer	Immunotherapy	Muc-1 and Interleukine 2 (IL-2)	Attenuated Vaccinia Virus (Ankara Strain)	Recombinant Attenuated Vaccinia Virus	Subcutaneous
B-GT/12	Cancer therapy	Non-Small Cell Lung cancer	Immunotherapy	Muc-1 and Interleukine 2 (IL-2)	Attenuated Vaccinia Virus (Ankara Strain)	Recombinant Attenuated Vaccinia Virus	Subcutaneous
B-GT/13	Cancer therapy	Refractory squamous cell carcinoma of the Head and Neck	Tumor suppressor gene	Wild-type p53	Human Adenovirus serotype 5	Recombinant Adenovirus D (E3, E1A, E1B)	Intratumoral
B-GT/14	Cancer therapy	Recurrent squamous cell carcinoma of the Head and Neck	Tumor suppressor gene	Wild-type p53	Human Adenovirus serotype 5	Recombinant Adenovirus D (E3, E1A, E1B)	Intratumoral
B-GT/15	Cancer therapy	Progressive metastatic renal cell carcinoma	Immunotherapy	Muc-1 and Interleukine 2 (IL-2)	Attenuated Vaccinia Virus (Ankara Strain)	Recombinant Attenuated Vaccinia Virus	Subcutaneous
B-GT/16	Cardiovascular therapy	Chronic angina pectoris	Gene therapy	human FGF-4	Human Adenovirus serotype 5	Recombinant Adenovirus D (E1A, E1B)	Intracoronary
B-GT/17	Infectious disease	AIDS	Immunotherapy	genes for the gag, protease and part of the reverse transcriptase proteins of HIV-1	Adeno Associated Virus serotype 2	Recombinant Adeno Associated Virus D (rep, cap)	Intramuscular
B-GT/18	Cancer therapy	Metastatic melanoma or other advanced solid tumors	Immunotherapy	Interleukine 2 (IL-2)	Human Adenovirus serotype 5	Recombinant Adenovirus D (E1, E3)	Intratumoral
B-GT/19	Cancer therapy	Operable high-grade glioma	Suicide gene/ pro drug	Thymidine Kinase (HSV-TK1)	Human Adenovirus serotype 5	Recombinant Adenovirus D (E1, E3)	Intratumoral
B-GT/20	Cardiovascular therapy	Stable angina pectoris	Gene therapy	human VEGF121	Human Adenovirus serotype 5	Recombinant Adenovirus D (E1a and partially E1b and E3)	Intracardiac
B-GT/21	Gastrointestinal disorders	Ulcerative colitis	anti-inflammatory treatment	human Interleukine 10 (HIl10)	Lactococcus lactis strainMG1363	Recombinant Lactococcus lactis D (thy A)	oral and rectal
B-GT/22	Hepatic disorders	Chronic hepatitis B	Immunotherapy	Hepatitis B virus polyepitope gene	Attenuated Vaccinia virus strain MVATGN33	Recombinant Attenuated Vaccinia Virus	subcutaneous
B-GT/23	Infectious disease	lower respiratory tract illness	Immunotherapy	genes expressing -hPIV3 fusion protein -RSV fusion protein -hemagglutinin-neuraminidase	Attenuated Bovine Parainfluneza Virus type 3 strain bPIV3/15626/84	Recombinant Attenuated Bovine Parainfluneza Virus	intranasal
B-GT/24	Cancer therapy	cervical neoplasia	Immunotherapy	-E6 and E7 genes from HPV -Interleukine 2 (IL-2)	Attenuated Vaccinia virus strain MVATGN33	Recombinant Attenuated Vaccinia virus	subcutaneous
B-GT/25	Infectious disease	AIDS	Immunotherapy	Gag, Pol, Nef genes of HIV	Attenuated measles virus Schwarz strain	Recombinant attenuated measles virus	intramuscular

[Home Page] [Previous Menu] [Search] Copyright ©2005 IPH-SBB  Contact  Privacy